Acrivastine

SKU: orb1302765

Description

Acrivastine

Research Area

Immunology & Inflammation, Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 87848-99-5
• MW: 348.44
• Purity: 99.85%
• Formula: C₂₂H₂₄N₂O₂
• SMILES: Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1
• Target: Histamine Receptor
• Solubility: DMSO:5 mg/mL (14.35 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.87 mM)

Bioactivity

• In Vivo:
  Acrivastine, administered typically at 8mg thrice daily, is a highly effective and well-tolerated antihistamine for managing chronic urticaria and allergic rhinitis, offering minimal drowsiness compared to clemastine and similar adverse effect profiles to placebo or terfenadine. It demonstrates superior efficacy over placebo and comparability to clemastine, hydroxyzine, chlorpheniramine, cyproheptadine, and terfenadine in treating histamine-related dermatoses. Both 4mg and 8mg doses notably improve symptoms of seasonal allergic rhinitis, including sneezing, runny nose, and overall discomfort, with the 8mg dose additionally reducing watery eyes and itchy throat symptoms. Therefore, acrivastine is recognized as both effective and well-tolerated in treating seasonal allergic rhinitis.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Acrivastin, Acrivastine, BW825C, inhibit, HistamineReceptor, Histamine Receptor, Inhibitor, H1 receptor, Semprex

Compound Identifiers

PubChem CID

5284514